Vicki Racicot, Field Application Scientist - Horizon Discovery

Leveraging screening of broad, diverse panels of cancer-relevant cell lines has historically yielded highly relevant data, which are used to identify mode-of-action, to expand disease or tissue efficacy, and to identify potential drug combinations. Results of such screens can drive the progression of novel oncology therapeutics from target validation through to the clinical phases of the discovery continuum. In this GEN webinar, we expand on how data generated from 2D cell panel single-agent and combination screens can complement data derived from a CRISPR knockout drug-gene interaction screen, leading to robust target identification and initial validation. The clinical-relevance of cell panel screens can be enhanced by integrating robust, high throughput methods for screening in three-dimensional models, including cell line-derived spheroids and patient-derived organoids. Finally, using selected case studies, we will highlight how 3D-specific phenotypic signatures align well with therapeutic target biology and the genetic background of the oncology model(s) being interrogated.